Biofrontera AG (BFRA)

Etorro trading 970x250

About Biofrontera AG

Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of lesion-directed and field-directed actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos, an over-the-counter line of skin care cosmetic products. In addition, it is developing Ameluz for the treatment of field cancerization and nodular basal cell carcinoma; BF-derm1 for the treatment of chronic and antihistamine-resistant urticaria; and BF-1 for the prophylactic treatment of migraine. Further, the company’s product portfolio includes Xepi, a prescription antibiotic cream for the treatment of impetigo; and Aktipak, a generic drug for the treatment of acne. It offers its products primarily in the United States, Europe, and Israel. The company has a collaboration and partnership agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany. Address: Hemmelrather Weg 201, Leverkusen, Germany, 51377

Biofrontera AG News and around…

Latest news about Biofrontera AG (BFRA) common stock and company :

12 Health Care Stocks Moving In Friday's Intraday Session
22 Oct, 2021 FinancialContent

Gainers Progenity (NASDAQ:PROG) stock increased by 18.48% to $2.96 during Friday's regular session. Progenity's ...

Biofrontera AG receives FDA-approval of the BF-RhodoLED® XL lamp
22 Oct, 2021 Yahoo! Finance

Leverkusen, Germany, Oct. 22, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the "Company"), an international biopharmaceutical company, today announced the approval of the new red-light source for photodynamic therapy (PDT), the BF-RhodoLED® XL, by the U.S. Food and Drug Administration (FDA). In accordance with FDA requirements, the approval was granted as a combination approval with our prescription drug Ameluz®, same as the approval with the predecessor

Biofrontera reports preliminary approximate revenues for the month of September 2021
01 Oct, 2021 Yahoo! Finance

Leverkusen, Germany, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported preliminary, unaudited revenue for the month of September 2021. The Company’s preliminary, unaudited revenue from product sales in September 2021 was in the range of EUR 2.3 and 2.5 million, compared to EUR 1.8 million in September 2020, an increase of about 33%. Preliminary revenues from product sales in t

12 Health Care Stocks Moving In Thursday's Intraday Session
30 Sep, 2021 FinancialContent

Gainers Progenity (NASDAQ:PROG) stock increased by 21.06% to $1.31 during Thursday's regular session. The current ...

Biofrontera reports preliminary revenue for the month of August 2021
08 Sep, 2021 FinancialContent
Biofrontera reports financial results for the six months ended June 30, 2021
19 Aug, 2021 FinancialContent
Biofrontera AG: Conference call to discuss half-year 2021 financial results to be held on August 20, 2021
12 Aug, 2021 FinancialContent
Biofrontera reports preliminary revenue for the month of July 2021
09 Aug, 2021 FinancialContent
Biofrontera To Sell Photodynamic Therapy For Skin Diseases In Poland Via Supply Pact With Medac
23 Jul, 2021 FinancialContent

Biofrontera Pharma GmbH, a wholly owned subsidiary ofBiofrontera AG(NASDAQ: BFRA) andMedac Gesellschaft f ...

Biofrontera enters into license and supply agreement with Medac for the marketing of Ameluz® in Poland
23 Jul, 2021 FinancialContent
Biofrontera Inc. seeks IPO in the USA
06 Jul, 2021 FinancialContent
Biofrontera reports preliminary revenue for the month of June 2021
06 Jul, 2021 FinancialContent
Biofrontera Stock Moves Higher On Outlining Clinical Update
22 Jun, 2021 FinancialContent

Biofrontera AG(NASDAQ: BFRA)has provided an updateon two submissions to the FDA, enabling the simultaneous use of ...

Biofrontera provides update on clinical developments
22 Jun, 2021 FinancialContent
Biofrontera reports preliminary revenue for the month of May 2021
07 Jun, 2021 FinancialContent
Biofrontera AG to Host Earnings Call
12 May, 2021 Yahoo! Finance

NEW YORK, NY / ACCESSWIRE / May 12, 2021 / Biofrontera AG (NASDAQ:BFRA) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 12, 2021 at 8:00 AM Eastern Time.To listen to the event live or access a replay of the call - visit https://www.

Biofrontera reports Q1 2021 financial results
11 May, 2021 FinancialContent
Earnings Scheduled For May 11, 2021
11 May, 2021 FinancialContent

Companies Reporting Before The Bell • Oxford Lane Capital (NASDAQ:OXLC) is estimated to report earnings for its fourth ...

72 Biggest Movers From Yesterday
07 May, 2021 FinancialContent

Gainers SemiLEDs Corporation (NASDAQ: LEDS) shares surged 85.8% to settle at $10.22 on above-average volume. Liquidity Services, ...

58 Stocks Moving In Thursday's Mid-Day Session
06 May, 2021 FinancialContent

Gainers Stealth BioTherapeutics Corp (NASDAQ: MITO) shares surged 92.9% to $2.3150. Stealth BioTherapeutics presented at the ...

Biofrontera reports preliminary revenue for the month of April 2021
06 May, 2021 FinancialContent
Biofrontera AG: First quarter conference call to be held on May 12, 2021
03 May, 2021 FinancialContent
Biofrontera reports results for the 2020 financial year
12 Apr, 2021 FinancialContent
Earnings Scheduled For April 12, 2021
12 Apr, 2021 FinancialContent

Companies Reporting Before The Bell • Aphria (NASDAQ:APHA) is projected to report earnings for its third ...

Biofrontera announces preliminary revenue for Q1 2021
08 Apr, 2021 FinancialContent
Biofrontera announces conference call to be held on April 13, 2021 to discuss fiscal year 2020 financial results
31 Mar, 2021 FinancialContent
Biofrontera submits application for FDA approval of new BF-RhodoLED® XL lamp
31 Mar, 2021 FinancialContent
12 Health Care Stocks Moving In Monday's Intraday Session
29 Mar, 2021 FinancialContent

Gainers Humanigen (NASDAQ:HGEN) shares increased by 78.62% to $24.99 during Monday's regular session. Trading volume ...

The Daily Biotech Pulse: FDA Nod For Astellas, Seagen, Gilead Get Positive Regulatory Tidings From Europe, 3 IPOs
26 Mar, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Biofrontera AG announces the closing of the capital raise with gross proceeds of EUR 24.7 million
26 Feb, 2021 FinancialContent

Biofrontera AG (BFRA) is a NASDAQ Common Stock listed in , ,

970x250